Kornimate/medical-research-clean huggingface dataset:
interprofessional pharmacogenomics (ipgx) registry and repository

Conditions: Diabetes; Cholesterol; Cancer; Blood Pressure Disorders; Heart Disease; Respiratory Ilness; COPD; Adverse Drug Reaction (ADR); Poly Pharmacy

Summary: this program collects genetic and health information to help doctors choose the right medications for patients.

this study wants to understand how genes can affect how the body responds to medicines. this information will help us determine whether changing your medicine can make you healthier and improve your life. we will study your medical history for the last year and the next five years after you join the study. study goals include: * enrolling patients who take multiple medications or have harmful side effects from their medications. * keeping all medical information and genetic samples from patients in one place. * helping doctors make better decisions about which medicines to prescribe. * influencing insurance companies and the government to help pay for this kind of medical care for people who need to change their medicine to stay healthy.

Eligibility criteria:
inclusion criteria: * the study will invite patients who are eligible for pgx workup/pgx care to participate, provided they meet the following criteria: use of five or more medications, including over the counter drugs, supplements, natural products, cannabis products, or other recreational drugs, or * individuals taking blood pressure or depression medications, even if less than five medications. * ability to understand and give consent. * able to consent to donate blood and/or urine samples and buccal swabs. * able to answer detailed questionnaires, including quarterly questionnaires about adrs, cognitive testing such as serial mini-mental status exams, and or quality of life questions. * able to understand that their health record and changes in health status will be followed for a five-year period and shared in deidentified form with the research community. * all genders. * any age over 18 years. exclusion criteria: * individuals admitted to hospice. * declines to participate or interact with staff/share their medical status. * a diagnosis of alzheimer's disease or related dementias in a medical record as this indicates a progressive, debilitating condition that impairs memory, thought processes, and functioning., * individuals who are unable or unwilling to provide consent. * unable to verbally communicate and comprehend english language

Keywords: registry repository polypharmacy adverse drug reaction
midostaurin (pkc412) for locally advanced rectal cancer

Conditions: Adenocarcinoma of the Rectum

Summary: this study combines midostaurin (pkc412) with radiation and a standard chemotherapy drug call 5-fluorouracil (5-fu) for subjects with advanced rectal cancer. midostaurin is a type of kinase inhibitor which works by blocking proteins associated with cancer cell growth. previous studies also suggest that midostaurin may help increase the effectiveness of radiation therapy. in this research we are looking for the highest dose of midostaurin that can be given safely in combination with standard chemoradiation.

midostaurin capsules will be taken by mouth for 8 weeks. for the first 2 weeks midostaurin will be taken alone (no chemoradiation). after 2 weeks standard chemoradiation will be added to the midostaurin regimen. subjects receive midostaurin and chemoradiation for an additional 6 weeks. physical exams will be done weekly. blood samples will be taken and an optional tumor biopsy will be performed in week 2. 4-5 weeks after completing chemoradiation and midostaurin subjects will undergo surgery as standard of care. tumor tissue from the surgery will be used for research purposes. a ct scan of chest, abdomen, and pelvis will be performed. after completion of surgery, subjects will have an end of study visit with physical exam, blood tests. ct scans of chest, abdomen, and pelvis will be performed yearly for 5 years.

Eligibility criteria:
inclusion criteria: * adenocarcinoma of the rectum * t3/4 or n+ disease * life expectancy \> 3 months * normal organ and marrow function exclusion criteria: * metastatic disease * pregnant or breastfeeding * prior radiotherapy * receiving other investigational agents * history of inflammatory bowel disease * active scleroderma or crest syndrome * uncontrolled intercurrent illness * history of a different malignancy unless disease free for at least 5 years * hiv or active viral hepatitis * impaired cardiac function

Keywords: rectal cancer chemotherapy chemoradiation
panadol osteo pharmaceuticals benefit scheme (pbs) claims cohort study

Conditions: Osteoarthritis

Summary: the aim of this observational study is to compare the use of an extended release paracetamol formulation with standard paracetamol in a cohort of australian concessional patients with osteoarthritis (oa), to assess differences in prescribing patterns and patient compliance.

this retrospective analysis of physician prescribing data (long-term concessional cohort from the medicare australia pbs claims dataset for the time period 2008-2011 (4 years) will compare the use of extended release paracetamol (panadol osteo) with standard paracetamol 500mg in a cohort of australian concessional patients with oa, to assess differences in prescribing patterns and patient compliance.

Eligibility criteria:
inclusion criteria: * participants prescribed with a paracetamol product and categorized as a concessional patient * participants with new episodes of oa (no history of oa paracetamol in previous 12 months) or suffering from chronic oa (history of oa paracetamol in the previous 12 months) exclusion criteria: * participants with rheumatoid arthritis or other auto-immune inflammatory conditions * participants receiving the following anti-rheumatoid therapies:immunimodulators such as methotrexate, leflunamide and tnf blockers * participants receiving treatment for cancer pain
acid pocket: position and aspiration

Conditions: GERD - PPI Responders; GERD - PPI Non-responders; Barrett Esophagus; Healthy Volunteers

Summary: gastroesophageal reflux disease (gerd) is a very common condition affecting up to 30% of adults. to date, therapy consists of powerful acid suppression with proton pump inhibitors (ppi). nevertheless, only 60-70% of gerd patients report complete symptom relief with this therapy. as the mechanisms underlying symptom perception in ppi resistant patients are not fully understood, there is currently no adequate therapy available. it is becoming increasingly clear that reflux, especially in the postprandial period, occurs from a reservoir of acid floating on top of the meal: the so-called "acid pocket". in this study, we aim to investigate further the acid pocket by determining its exact position and chemical contents between healthy volunteers, gerd patient who respond well and bad to ppi therapy and gerd patients with barrett's esophagus.

a costume made multi-ph-impedance manometry catheter will be placed in the esophagus and clipped to the z-line. patients then will be given a standardized meal and the position of the acid pocket will be measured. after two hours the pocket will be aspirated through a gastric catheter. then, patients will be allowed to return home and the study will be continued for another 22 hours. the special catheter will be removed at the end of the study. collected acid pockets will be used to analyze content and perform permeability experiments. data of the 24-hour experiment will be used to evaluate the position of the acid pocket and number of reflux episodes.

Eligibility criteria:
inclusion criteria: * signed informed consent * older than 18 years * fit to criteria of 'study population' (hv, ppi responder, ppi non-responder, barrett) exclusion criteria: * pregnancy

Keywords: acid pocket gerd barrett
optimization of a digital self-guided psychological intervention for insomnia: a randomized factorial experiment

Conditions: Insomnia

Summary: in a previous pilot study, a digital self-guided intervention for insomnia showed preliminary positive effects on insomnia symptoms. in order to optimize the digital self-guided format, this study will evaluate the added value of three treatment features on treatment engagement and insomnia symptoms. the participants will be adults with insomnia. the trial will be a 2x2x2 randomized factorial experiment, where the following features/factors will be manipulated: an optimized graphical user interface (yes or no), an adaptive treatment strategy (yes or no), and daily prompts to use the intervention (yes or no). the factorial experiment will create 8 equally large groups (1:1:1:1:1:1:1:1), who will receive the different combinations of features. the main outcome will be the effect on treatment engagement.


Eligibility criteria:
inclusion criteria: 1. ≥ 18 years of age. 2. ≥ 15 points on insomnia severity index. 3. insomnia diagnosis, according to criteria in the diagnostic and statistical manual of mental disorders-5 (somatic/psychiatric comorbidity is allowed). 4. good understanding of the swedish language. 5. no practical obstacles to participate in treatment and assessments. 6. daily access to computer/smart-phone/tablet with internet access. 7. can receive phone calls and text messages during the study period. exclusion criteria: 1. sleep diseases, such as narcolepsy or sleep apnea. 2. somatic or psychiatric illnesses that either are directly contraindicated for the treatment, require other treatment, or entail symptoms/a functional level making it too difficult to participate in the study. 3. alcohol/drug abuse, or medication with side effects on sleep (however, sleep medication is allowed). 4. working nights or night shifts.

Keywords: insomnia icbt factorial experiment optimization user interface adaptive treatment strategy prompts digital intervention
a study of subcutaneous mircera in patients with chronic kidney disease, not on dialysis.

Conditions: Anemia

Summary: this 2 arm study will compare the efficacy and safety of mircera and darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease who are not on dialysis and who are receiving subcutaneous darbepoetin alfa maintenance therapy. patients will be randomized either to remain on darbepoetin alfa therapy as per local label, or to switch to monthly subcutaneous mircera, at a starting dose of 120, 200 or 360 micrograms, depending on the weekly dose of darbepoetin alfa administered prior to the first dose of mircera. the anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age; * chronic kidney disease, not requiring dialysis; * receiving darbepoetin alfa maintenance therapy for \>=8 weeks before screening, and during screening/baseline period. exclusion criteria: * overt gastrointestinal bleeding within 8 weeks before screening, or during screening/baseline period; * transfusion of red blood cells within 8 weeks before screening, or during screening/baseline period; * active malignant disease; * previous treatment with mircera.
contraceptive use and respiratory conditions among scottish women

Conditions: Asthma

Summary: studies examining the sex differences in the epidemiology and morbidity patterns of asthma show that the rates of disease severity, healthcare utilisation, and poor quality of life are considerably higher in women than in men, and this has been attributed to endogenous and exogenous sex hormonal factors. studies examining the impact of use of hormonal contraceptives on the risk of asthma and asthma-related conditions are few, yet findings are conflicting. in the present study, the investigators utilize data from the scottish health survey, a national representative sample, to investigate the associations between current use of hormonal contraceptives and the prevalence of self-reported doctor-diagnosed current asthma and wheezing symptoms in scottish women. the investigators hypothesize that while current use of any hormonal contraceptives and combined oral pills are associated with higher prevalence of asthma and asthma outcomes, current use of progesterone-only contraceptives is not associated with asthma. a secondary aim of the current study is to examine whether there is evidence of any biological interaction between use of hormonal contraceptives and bmi in relation to the risk of asthma and asthma outcomes.


Eligibility criteria:
inclusion criteria: * non-pregnant * woman * 16-45 years old exclusion criteria: * pregnant * man * younger than 16 years or older than 45 years old

Keywords: hormonal contraceptives combined pills progesterone-only contraceptives body mass index asthma scotland women
systematic team approach to guide early mobilization in surgical intensive care unit patients

Conditions: Muscle Weakness; Critical Illness; Respiratory Insufficiency

Summary: the investigators hypothesize that by applying a validated algorithm to accomplish early mobilization in surgical intensive care unit (icu) patients, these patients will achieve a higher level of mobility which translates to shorter icu length of stay and improved functional status at discharge. additionally, the investigators hypothesize that genetic polymorphisms related to muscle strength and sleep will also explain some variance in these outcome variables.

the trauma literature consistently shows that early mobilization improves patients' outcome after a localized trauma such as hip fracture, or blunt solid organ injuries. in addition, in critically ill patients on the medical icu, early mobilization improves patients' functional outcome and decreases icu length of stay (1). this study evaluates if critically ill patients in a surgical icu can safely and effectively be mobilized early after trauma and surgery. the investigators propose to conduct a randomized controlled study in surgical intensive care unit patients to evaluate the effects of msoms guided early mobilization. additionally, the study will examine known genetic polymorphisms as related to sleep quality and muscle strength and how it relates to early mobilization of surgical icu patients. in particular, the study will focus on the following polymorphisms: clock, npas2, per2 and per3, pde4d,muc1, atp2b1, dcdc5, trpm6, shroom3, and mds1 genes.

Eligibility criteria:
inclusion criteria: * adults (18 years of age or greater) * who have been on mechanical ventilation for less than 48 hours and are expected to continue for at least 24 more hours * who meet criteria for baseline functional independence (barthel index greater than or equal to 70 obtained from a proxy describing patient function 2 weeks before admission exclusion criteria: * irreversible disorders with 6-month mortality greater than 50% * rapidly developing neuromuscular disease * cardiopulmonary arrest * motor component of glascow coma scale \<5 * elevated intracranial pressure * ruptured/leaking aortic aneurysm * acute mi before peak troponin has been reached * absent lower limbs * pregnancy * unstable fractures contributing to likely immobility * hospitalization prior to icu admission \>5 days * enrollment in another clinical trial

Keywords: muscle strength functional mobility outcome intensive care unit quality of life
prevention of weight gain

Conditions: Obesity; Body Weight Changes

Summary: the purpose of this study is to test methods for preventing weight gain in normal-weight and overweight women aged 25 through 44. participants will complete brief questionnaires about their health, eating and exercise habits, and use of weight control strategies. they will then be randomly assigned to 1 of 3 treatment conditions. all 3 treatments receive information on the importance of maintaining a healthy body weight, the components of a healthy diet, and ways to increase activity levels. the 3 treatment differ in how this information is delivered. at 12, 24 and 36 months after enrolling in the study, participants will attend assessment sessions. they will complete questionnaires and have body weight measured.


Eligibility criteria:
inclusion criteria: * body mass index of 21 through 30 exclusion criteria: * presence of chronic disease that precludes regular physical activity or changes in dietary intake * currently receiving treatment for psychological disorder * currently pregnant or having given birth within last 12 months * use in last 3 months of weight loss medications or other drugs that affect body weight * participation in a weight loss program in last 12 months * planning to relocate outside the study area in the next 3 years

Keywords: weight gain
combined effect of limicol and physical activity on ldl cholesterol and muscle function.

Conditions: Hypercholesterolemia

Summary: cardiovascular disease (cvd), foremost among which ischemic heart disease and stroke, are the leading cause of mortality and morbidity in france. these diseases are multifactorial origin and even if it is not possible to act on risk markers such as age, sex, or heredity, risk factors like high cholesterol, smoking , hypertension, obesity, diabetes and physical inactivity, are the main target of prevention strategies. dydlipidemias have a role in the formation of cvd in participating in the genesis of atherosclerosis. the cholesterol and ldl-cholesterol in particular is subject to oxidation process in plasma. the molecules of oxidized ldl-cholesterol, small and dense, easily penetrate the arterial endothelial wall and are greeted by macrophages. following a succession of different processes including inflammation, atherosclerotic plaque is formed. the result is either an arteriopathy when the arterial lumen narrowing, or atherothrombosis in the event of plaque rupture. given this pathophysiology, reduce blood lipids, including ldl-cholesterol and reducing oxidation and inflammation are interesting strategies in the context of cardiovascular prevention. several scientific study showed that nutritional supplementation with some plant extracts such as artichokes, garlic, red yeast rice, or the sugar cane policosanol helps to reduce several cardiovascular risk factors including regulate concentrations of circulating lipids. in this study, we hypothesize that the food supplement limicol contributes to reducing ldl cholesterol in the context of care for patients (dietary measures and physical activity)


Eligibility criteria:
inclusion criteria: * bmi between 25 and 35 kg/m² * subject has a stable weight for at least three months before the start of the study. * ldl ≥ 1.50 g/l * 0.9 g/l ≤ triglycerides ≤ 4.00 g/l * subject able and willing to comply with the protocol and agreeing to give his informed consent in writing; * subject affiliated with a social security scheme exclusion criteria: * subject having a confirmed or suspected food allergy, notably to one of the components of the study product; * subject suffering from a severe chronic condition deemed incompatible with participation in the study by the investigator * subject with glaucoma * subject with uretroprostatic disorder * subjet anxious (score \>9 had scale) * subject with diabetes * subjet with treatment anticoagulant

Keywords: hypercholesterolemia ldl cholesterol
monitor patients with sleep apnea

Conditions: Sleep Apnea

Summary: the primary objective of the study is to gather data to correlate physiological signals measured by the avivo™ mobile patient management system with the patient's respiratory status, including apnea and hypopnea events, during polysomnography

patients with suspected sleep disordered breathing will be monitored during polysomnography and the collected information will be used to assess patient's respiratory status.

Eligibility criteria:
inclusion criteria: * is female or male, 18 years of age or older * undergoing polysomnography for suspected sleep apnea * is willing to provide written informed consent and comply with study guidelines
investigation of the tolerability of two facial cleansing routines for mild to moderate acne

Conditions: Acne

Summary: the objective of this study is to compare tolerability of two similar commercially available over the counter acne regimens (geologie and proactiv) in individuals with mild to moderate acne vulgaris over a 12-week daily treatment course.

acne vulgaris is a common, chronic inflammatory skin disorder that originates in the pilosebaceous unit. acne typically begins in adolescence and often continues into adulthood, with about 20% of cases resulting in scars or hyperpigmentation. it's estimated that acne affects about 85% of adolescents. individuals who experience acne and acne scars tend to also experience a negative impact on their social and mental health, including depression, anxiety, and social withdrawal. currently, topical solutions and lifestyle changes are the primary treatment for mild to moderate acne. this study will evaluate and compare the efficacy of two over the counter products in treating individuals with mild to moderate acne: geologie and proactive. both sets of products will be provided to northwestern in identical, unlabeled bottles for the purpose of blinding.

Eligibility criteria:
inclusion criteria: * 18 years or older * no known active skin infection. * presence of mild or moderate acne on face (clinical diagnosis or self-report) * willingness to give written consent and comply with study procedures. exclusion criteria: * active skin infection. * inability to understand instructions or procedures involved. * known allergy to ingredient(s) in products being used for study. * pregnant women, prisoners, and vulnerable populations. * has a history of acute or chronic disease that may interfere with or increase the risk of study participation. * has any dermatological disorder that may interfere with the accurate evaluation of the subject's facial appearance, based on the opinion of the investigator.